DrugRanks
  • Home
  • Overview
  • Medical Conditions
    • Overactive Bladder
    • Pain: Non-prescription drugs
    • Post-Operative Analgesics
    • Relapsing Remitting Multiple Sclerosis (RRMS)
    • RRMS-HDA
  • FAQs
  • About DrugRanks
    • London School of Economics
    • Staff
    • Decision conferences
  • Join our email list
  • Home
  • Overview
  • Medical Conditions
    • Overactive Bladder
    • Pain: Non-prescription drugs
    • Post-Operative Analgesics
    • Relapsing Remitting Multiple Sclerosis (RRMS)
    • RRMS-HDA
  • FAQs
  • About DrugRanks
    • London School of Economics
    • Staff
    • Decision conferences
  • Join our email list
Search by typing & pressing enter

YOUR CART

About DrugRanks


CBSAD (Comparative Benefit-Safety Assessment of Drugs) is the process of comparing and modelling the benefit-safety balance of prescription drugs for a medical condition. ​ The model is based on multi-criteria decision analysis (MCDA).
DrugRanks Lawrence Phillips LSE
​DrugRanks is the organisation that applies the CBSAD process. Our aim is to improve decisions about prescription drugs, and so improve public health.
​DrugRanks brings experts, prescribers and patients together in a facilitated workshop called a ‘decision conference’. The group establishes the key favourable and unfavourable effects of the drugs, considers the available evidence and judges the clinical relevance of the effects. 

​Software based on decision theory combines the data and judgements, enabling the overall benefit-safety rating of each drug to be summarised in a single 'Figure of Merit' number.

​Displaying the numbers graphically reveals which drugs are most beneficial and safest. The clarity of the results makes it possible to create brief written descriptions of the relative advantages and disadvantages of each individual drug. ​​

Staff

Decision Conferences

FAQs

​Copyright © 2020 DrugRanks 
Privacy Policy